Pharmacological modulation of cognitive and behavioral symptoms in patients with dementia due to Alzheimer's disease

Journal of the Neurological Sciences

Volumn 336, Issue 1-2, 2014, Pages 103-108

  De Oliveira, Fabricio Ferreira ^a   Bertolucci, Paulo Henrique Ferreira ^a   Chen, Elizabeth Suchi ^a   Smith, Marilia De Arruda Cardoso ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Alzheimer disease; Cognitive disorders; Dementia; Drug therapy; Neurodegenerative diseases; Neuropsychiatry

Indexed keywords

ANTICONVULSIVE AGENT; APOLIPOPROTEIN E4; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; VALPROIC ACID;

ADULT; AGED; AGITATION; ALCOHOL CONSUMPTION; ALZHEIMER DISEASE; APATHY; ARTICLE; BEHAVIOR DISORDER; BRAZILIAN VERSION OF THE ZARIT CAREGIVER BURDEN INTERVIEW; CAREGIVER BURDEN; CLINICAL DEMENTIA RATING; CLOCK DRAWING TEST; COGNITIVE DEFECT; DELUSION; DEMENTIA; DEMOGRAPHY; DISEASE DURATION; DISEASE SEVERITY; DYSPHORIA; EDUCATIONAL STATUS; EUPHORIA; FEMALE; FUNCTIONAL STATUS; HALLUCINATION; HAPLOTYPE; HUMAN; INDEX OF INDEPENDENCE IN ACTIVITIES OF DAILY LIVING; IRRITABILITY; LIVING LAWTON SCALE FOR INSTRUMENTAL ACTIVITIES OF DAILY LIVING; LOCOMOTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINI MENTAL STATE EXAMINATION; MOTOR DYSFUNCTION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OBESITY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SMOKING; SURVIVAL; VERY ELDERLY;

ALZHEIMER DISEASE; COGNITIVE DISORDERS; DEMENTIA; DRUG THERAPY; NEURODEGENERATIVE DISEASES; NEUROPSYCHIATRY;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BEHAVIORAL SYMPTOMS; COGNITION DISORDERS; DEMENTIA; FEMALE; HUMANS; MALE; MEMANTINE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS;

EID: 84892596532     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2013.10.015     Document Type: Article

References (33)

1. R. Liperoti, C. Pedone, K.L. Lapane, V. Mor, R. Bernabei, and G. Gambassi Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents Arch Intern Med 165 2005 2677 2682
2. L.S. Schneider, P.N. Tariot, K.S. Dagerman, S.M. Davis, J.K. Hsiao, and M.S. Ismail et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease N Engl J Med 355 2006 1525 1538
3. J.-Y. Shin, N.-K. Choi, S.-Y. Jung, J. Lee, J.S. Kwon, and B.-J. Park Risk of ischemic stroke with the use of risperidone, quetiapine and olanzapine in elderly patients: a population-based, case-crossover study J Psychopharmacol 27 2013 638 644
4. G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack Jr., and C.H. Kawas et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup Alzheimers Dement 7 2011 263 269
5. J.L. Cummings, M. Mega, K. Gray, S. Rosenberg-Thompson, D.A. Carusi, and J. Gornbein The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia Neurology 44 1994 2308 2314
6. M.F. Folstein, S. Folstein, and P.R. McHugh Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 1975 189 198
7. L.E. Harrell, D. Marson, A. Chatterjee, and J.A. Parrish The Severe Mini-Mental State Examination: a new neuropsychologic instrument for the bedside assessment of severely impaired patients with Alzheimer disease Alzheimer Dis Assoc Disord 14 2000 168 175
8. J.C. Morris The Clinical Dementia Rating (CDR): current version and scoring rules Neurology 43 1993 2412 2414
9. M. Freedman, L. Leach, E. Kaplan, G. Winocur, K.I. Shulman, and D.C. Delis Clock drawing: a neuropsychological analysis 1994 Oxford University Press New York
10. S. Katz, and C.A. Akpom A measure of primary socio-biological functions Int J Health Serv 6 1976 493 508
11. M.P. Lawton Instrumental Activities of Daily Living (IADL) scale: self-reported version Psychopharmacol Bull 24 1988 789 791
12. A. Taub, S.B. Andreoli, and P.H.F. Bertolucci Dementia caregiver burden: reliability of the Brazilian version of the Zarit Caregiver Burden Interview Cad Saude Publica 20 2004 372 376
13. M. Del Prete, S. Spaccavento, A. Craca, P. Fiore, and P. Angelelli Neuropsychiatric symptoms and the APOE genotype in Alzheimer's disease Neurol Sci 30 2009 367 373
14. M.F. Weiner, R.E. Tractenberg, M. Sano, R. Logsdon, L. Teri, and D. Galasko et al. No long-term effect of behavioral treatment on psychotropic drug use for agitation in Alzheimer's disease patients J Geriatr Psychiatry Neurol 15 2002 95 98
15. J.A. Mortimer, B. Ebbitt, S.P. Jun, and M.D. Finch Predictors of cognitive and functional progression in patients with probable Alzheimer's disease Neurology 42 1992 1689 1696
16. F.A. Schmitt, C.H. van Dyck, C.H. Wichems, and J.T. Olin Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis Alzheimer Dis Assoc Disord 20 2006 255 262
17. H.H. Feldman, F.A. Schmitt, and J.T. Olin Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment Alzheimer Dis Assoc Disord 20 2006 263 268
18. J.L. Cummings, E. Schneider, P.N. Tariot, and S.M. Graham Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment Neurology 67 2006 57 63
19. B. Winblad, R.W. Jones, Y. Wirth, A. Stöffler, and H.J. Möbius Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials Dement Geriatr Cogn Disord 24 2007 20 27
20. F. Clerici, N. Vanacore, A. Elia, S. Spila-Alegiani, S. Pomati, and R. Da Cas et al. Memantine effects on behaviour in moderately severe to severe Alzheimer's disease: a post-marketing surveillance study Neurol Sci 33 2012 23 31
21. A. Atri, L.W. Shaughnessy, J.J. Locascio, and J.H. Growdon Long-term course and effectiveness of combination therapy in Alzheimer's disease Alzheimer Dis Assoc Disord 22 2008 209 221
22. R. Howard, R. McShane, J. Lindesay, C. Ritchie, A. Baldwin, and R. Barber et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease N Engl J Med 366 2012 893 903
23. O.L. Lopez, J.T. Becker, A.S. Wahed, J. Saxton, R.A. Sweet, and D.A. Wolk et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease J Neurol Neurosurg Psychiatry 80 2009 600 607
24. J.L. Cummings The Neuropsychiatric Inventory: assessing psychopathology in dementia patients Neurology 48 1997 S10 S16
25. L.S. Schneider, P.S. Insel, and M.W. Weiner Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative Arch Neurol 68 2011 58 66
26. C. Ballard, A. Corbett, R. Chitramohan, and D. Aarsland Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions Curr Opin Psychiatry 22 2009 532 540
27. S. Gauthier, and J.L. Molinuevo Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease Alzheimers Dement 9 2013 326 331
28. S. Gauthier, Y. Wirth, and H.J. Möbius Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies Int J Geriatr Psychiatry 20 2005 459 464
29. S. Srikanth, A.V. Nagaraja, and E. Ratnavalli Neuropsychiatric symptoms in dementia-frequency, relationship to dementia severity and comparison in Alzheimer's disease, vascular dementia and frontotemporal dementia J Neurol Sci 236 2005 43 48
30. R.J. Howard, E. Juszczak, C.G. Ballard, P. Bentham, R.G. Brown, and R. Bullock et al. Donepezil for the treatment of agitation in Alzheimer's disease N Engl J Med 357 2007 1382 1392
31. T.R.E. Barnes, S. Banerjee, N. Collins, A. Treloar, S. McIntyre, and C. Paton Antipsychotics in dementia: prevalence and quality of antipsychotic drug prescribing in UK mental health services Br J Psychiatry 201 2012 221 226
32. L.P. Wadsworth, N. Lorius, N.J. Donovan, J.L. Locascio, D.M. Rentz, and K.A. Johnson et al. Neuropsychiatric symptoms and global functional impairment along the Alzheimer's continuum Dement Geriatr Cogn Disord 34 2012 96 111
33. S. Kavanagh, B. Van Baelen, and B. Schäuble Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study J Alzheimers Dis 27 2011 521 530